📢Discover this #EASLStudio episode to learn more about how the gut #microbiome impacts liver health:

📺Watch easlcampus.eu/videos/easl-st…
🎧Listen easlcampus.eu/podcasts/easl-…

#LiverTwitter #EduTwitter

Our RCT➡️⬇️ #alcohol drinking post #FMT in #cirrhosis pubmed.ncbi.nlm.nih.gov/32750174
Question
Are #microbiota enough for this ? YES!
Stools, but🚫supernatants from pts post #FMT ⬇️drinking in GF mice thru #SCFA
⬆️ #intestine RNAseq changes>>liver or brain
Read⤵️
rdcu.be/cXTxo

🔥Tomorrow 10/19, 12pm EDT🔥
Patty Pringle Bloom, M.D. Andrew Moon American Gastroenterological Association (AGA)
#LiverTwitter #GITwitter #MedTwitter
#HCC #Encephalopathy #Telehealth

Our important novel study of largest pTIPSS patients to date - no difference in survival between pTIPSS <72h vs 3-28days. 72h timeframe is impractical & based on historic rebleeding data. #livertwitter
onlinelibrary.wiley.com/doi/10.1111/ap…

Bariatric surgery is a great option for people with #NAFLD

But observational data supporting it is tricky

👀this nice paper: jama.jamanetwork.com/article.aspx?d…

How long does it take for surgery to prevents CV events? Could protection happen before surgery? Within 6 months?
#livertwitter

#MentoringAdvice When I was on call in the past, I asked my fellows: please call me if you have any doubt.

Only Juan Turnes and Juan G Abraldes used to call me, and they are now very successful.

ASKING for HELP is not a sign of weakness, but shows self-confidence.

#livertwitter

Under-utilization of #NSBB in compensated #cirrhosis

👉🏻We need to do more to 🌉 between guidelines and clinical practice.

Thanks for highlighting this! #LiverTwitter #Gitwitter

Evaluation of practice of beta blockers prescription in patients with compensated cirrhosis in Asia Pacific region. #livertwitter
doi.org/10.1016/j.jceh…

Happy to share our new article in press GIE 🔥
In our PS analysis, we found that prophylactic clipping 🛠 did not reduce risk of post-polypectomy #bleeding 🩸 in #aspirin users 💊

CUHK Medicine CUHK Gastroenterology & Hepatology Francis KL Chan Raymond Tang Rashid Lui 雷諾信

pubmed.ncbi.nlm.nih.gov/36209766/

Questions from Mattias Mandorfer, answers from Aldo J. Montano-Loza
❓Why is graft rejection not used as an endpoint?
🗣️Was not asscociated with worse clinical outcomes

❓Or time-dependent covariate?
🗣️Small number and difficult to analyse
#EASLJC #LiverTwitter

Don't miss the next #EASLJC
Start preparing by reading the Journal of Hepatology article:
👉journal-of-hepatology.eu/cms/10.1016/j.…

Registration coming soon!

rajmookerjee poisson johanne Ahmed Elsharkawy Virginia

I've been loving UMichGIHep-Fellowship GR lectures - Dr Sanogo discussed endovascular management of portal HTN

Many benefits of TIPS: alleviation of portal HTN,⬆️iontrophic🫀function, improved renal function

BRTO: can improve isolated gastric varices but ⬆️portal pressures

#livertwitter

Adverse events in the placebo arm of NASH trials

➡️ 68% on placebo experience AEs

➡️ Pruritus in 10% receiving placebo in bile modulating agents trials

➡️ Useful comparator/benchmark for AEs in trials

New data from Rohit Loomba Mark Muthiah AJG - The American Journal of Gastroenterology

journals.lww.com/ajg/abstract/9…

Elliot Tapper Lorenz Balcar Thomas Reiberger All things considered, stage will always be key (see NAFLD/NASH activity vs. fibrosis discussion), but the only thing that you can modify at a given point is the speed of traveling.